SCHEMBL18068166

SCHEMBL18068166

Cc1c(CN2C(=O)c3ccccc3C2=O)cc(-c2cnc(C(F)(F)F)nc2)nc1C1CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
RECQL P46063 1/20 0.35
MCHR1 Q99705 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
TRPA1 O75762 4/20 0.34
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
GRM5 P41594 1/20 0.33
PTGES O14684 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2B Q13224 1/20 0.33
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
XPO1 O14980 1/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ACHE P22303 1/20 0.32
MEN1 O00255 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17979243 0.90 MAPT (0.35) MAPTRECQLMCHR1SMN1; SMN2TRPA1
SCHEMBL29639459 0.80 JUN (0.38) MAPTSMN1; SMN2TRPA1PTGESALDH1A1
SCHEMBL17979461 0.80 JUN (0.38) MAPTSMN1; SMN2TRPA1PTGESALDH1A1
SCHEMBL16634934 0.79 TRPA1 (0.40) MAPTRECQLSMN1; SMN2TRPA1RXFP1
SCHEMBL29411273 0.79 TRPA1 (0.43) MAPTRECQLSMN1; SMN2TRPA1CHRM5
SCHEMBL17979258 0.79 TRPA1 (0.43) MAPTRECQLSMN1; SMN2TRPA1CHRM5
SCHEMBL18068169 0.78 MCHR1 (0.35) MCHR1TRPA1PTGES
SCHEMBL18068164 0.77 MAPT (0.44) MAPTRECQLSMN1; SMN2PDCD1CD274
SCHEMBL16635833 0.76 MAPT (0.40) MAPTSMN1; SMN2TRPA1RXFP1GRM5
SCHEMBL17979121 0.76 ALDH1A1 (0.39) MAPTRECQLMCHR1SMN1; SMN2TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264567-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GENENTECH, INC. (US) 2016-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264567-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS TRPA1, TRPV1, TRPV5 MAPT 4093/4885RECQL 2373/4885MCHR1 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.